Meissner

Executive Summary

Meissner is a privately held global leader in the design and manufacture of critical filtration products and single-use systems for the biopharmaceutical industry. Founded in 1984, the company provides microfiltration solutions, stainless steel housings, filter integrity test instruments, and specialized platforms such as the CryoVault® freeze-thaw system. These products are engineered to reduce risk, ensure quality, and support regulatory compliance in the production of critical therapeutics. With a strong reputation for reliability and innovation, Meissner has established itself as a key partner to biopharma manufacturers worldwide. The company's focus on single-use technologies aligns with industry trends toward flexibility, cost reduction, and faster time-to-market. Despite being private and lacking publicly disclosed financials, Meissner's sustained growth and market position suggest a stable and profitable operation. The increasing demand for biologics and advanced therapies bodes well for the company's continued relevance and expansion.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation single-use filtration platform70% success
• Q2 2026Strategic partnership with a top-20 pharma for CryoVault adoption50% success
• TBDExpansion of manufacturing capacity in Ireland or US60% success